Can a drug cocktail cure metastatic breast cancer? a trial aims to find out

NCT ID NCT06439693

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase II trial tests whether a planned sequence of targeted therapies can eliminate HER2+ metastatic breast cancer and allow patients to stop treatment. The study enrolls people with stage IV HER2+ breast cancer at diagnosis. Participants receive a series of drug combinations over time, with the goal of achieving long-term remission without ongoing therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A sequence of drugs: a taxane (paclitaxel, docetaxel, or nab-paclitaxel) plus trastuzumab and pertuzumab, followed by trastuzumab deruxtecan, then tucatinib plus ado-trastuzumab emtansine (T-DM1), and finally trastuzumab plus pertuzumab plus tucatinib.
What this could lead to
If successful, this approach could point toward a cure for HER2+ metastatic breast cancer, allowing patients to stop treatment and remain cancer-free.
What could go wrong
This is an early-phase trial with a small number of participants, so the sequence may not work as hoped. The drugs can cause serious side effects, and the treatment is intense and lengthy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.